View Full Version : Guidelines regarding the use of Adalimumab (Humira) for severe psoriasis

07-06-2008, 09:00 PM
The National Institute for Health and Clinical Excellence (NICE) have issued their guidelines regarding the use of Adalimumab to treat psoriasis. NICE have recommended Adalimumab be prescribed when "the condition is severe" - defined by a PASI score greater than 10 and a DLQI score greater than 10, and "their condition has not improved with other treatments such as ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet radiation), or they have had side effects with these in the past or there is a medical reason why they should not be given these treatments."

To read the guidelines, please follow the link to the NICE website (http://www.nice.org.uk/guidance/index.jsp?action=byID&o=12007). For further information on Adalimumab, please click here (http://www.psoriasis-association.org.uk/adalimumab.html)